165 related articles for article (PubMed ID: 21464612)
1. Monoclonal antibodies for copper-64 PET dosimetry and radioimmunotherapy.
Bryan JN; Jia F; Mohsin H; Sivaguru G; Anderson CJ; Miller WH; Henry CJ; Lewis MR
Cancer Biol Ther; 2011 Jun; 11(12):1001-7. PubMed ID: 21464612
[TBL] [Abstract][Full Text] [Related]
2. Comparative uptakes and biodistributions of internalizing vs. noninternalizing copper-64 radioimmunoconjugates in cell and animal models of colon cancer.
Bryan JN; Jia F; Mohsin H; Sivaguru G; Miller WH; Anderson CJ; Henry CJ; Lewis MR
Nucl Med Biol; 2005 Nov; 32(8):851-8. PubMed ID: 16253810
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.
Niu G; Sun X; Cao Q; Courter D; Koong A; Le QT; Gambhir SS; Chen X
Clin Cancer Res; 2010 Apr; 16(7):2095-105. PubMed ID: 20215534
[TBL] [Abstract][Full Text] [Related]
4. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
5. Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis.
Knogler K; Grünberg J; Zimmermann K; Cohrs S; Honer M; Ametamey S; Altevogt P; Fogel M; Schubiger PA; Novak-Hofer I
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):603-11. PubMed ID: 17255283
[TBL] [Abstract][Full Text] [Related]
6. Maximum tolerated dose and large tumor radioimmunotherapy studies of 64Cu-labeled monoclonal antibody 1A3 in a colon cancer model.
Connett JM; Buettner TL; Anderson CJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3207s-3212s. PubMed ID: 10541365
[TBL] [Abstract][Full Text] [Related]
7. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.
DeNardo GL; DeNardo SJ; O'Donnell RT; Kroger LA; Kukis DL; Meares CF; Goldstein DS; Shen S
Clin Lymphoma; 2000 Sep; 1(2):118-26. PubMed ID: 11707820
[TBL] [Abstract][Full Text] [Related]
8. Harnessing
Keinänen O; Fung K; Brennan JM; Zia N; Harris M; van Dam E; Biggin C; Hedt A; Stoner J; Donnelly PS; Lewis JS; Zeglis BM
Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28316-28327. PubMed ID: 33106429
[TBL] [Abstract][Full Text] [Related]
9. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
[TBL] [Abstract][Full Text] [Related]
10. PET Imaging of Dll4 Expression in Glioblastoma and Colorectal Cancer Xenografts Using (64)Cu-Labeled Monoclonal Antibody 61B.
Zhou B; Wang H; Liu R; Wang M; Deng H; Giglio BC; Gill PS; Shan H; Li Z
Mol Pharm; 2015 Oct; 12(10):3527-34. PubMed ID: 26288060
[TBL] [Abstract][Full Text] [Related]
11. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV
Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889
[TBL] [Abstract][Full Text] [Related]
12. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models.
Niu G; Li Z; Xie J; Le QT; Chen X
J Nucl Med; 2009 Jul; 50(7):1116-23. PubMed ID: 19525473
[TBL] [Abstract][Full Text] [Related]
13. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.
Qi S; Hoppmann S; Xu Y; Cheng Z
Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.
Wong JY; Chu DZ; Williams LE; Liu A; Zhan J; Yamauchi DM; Wilczynski S; Wu AM; Yazaki PJ; Shively JE; Leong L; Raubitschek AA
Cancer Biother Radiopharm; 2006 Apr; 21(2):88-100. PubMed ID: 16706629
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3.
Cai W; Wu Y; Chen K; Cao Q; Tice DA; Chen X
Cancer Res; 2006 Oct; 66(19):9673-81. PubMed ID: 17018625
[TBL] [Abstract][Full Text] [Related]
18. Development of a two-antibody model for the evaluation of copper-64 radioimmunotherapy.
Bryan JN; Lewis MR; Henry CJ; Owen NK; Zhang J; Mohsin H; Jia F; Sivaguru G; Anderson CJ
Vet Comp Oncol; 2004 Jun; 2(2):82-90. PubMed ID: 19379188
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of 64Cu labeled GX1: a phage display peptide probe for PET imaging of tumor vasculature.
Chen K; Sun X; Niu G; Ma Y; Yap LP; Hui X; Wu K; Fan D; Conti PS; Chen X
Mol Imaging Biol; 2012 Feb; 14(1):96-105. PubMed ID: 21360213
[TBL] [Abstract][Full Text] [Related]
20. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
